MRK Jan 2024 90.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:19PM EDT. Market open.
| Previous close | 9.05 |
| Open | 9.15 |
| Bid | 9.70 |
| Ask | 10.10 |
| Strike | 90.00 |
| Expiry date | 2024-01-19 |
| Day's range | 9.15 - 10.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 359 |
- Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
RAHWAY, N.J., March 27, 2023--KEYTRUDA® Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma
- Zacks
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Zacks
The Zacks Analyst Blog Highlights Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton
Merck, Intel, MercadoLibre, The Travelers Companies and Halliburton are part of the Zacks top Analyst Blog.
© 2023 Yahoo. All rights reserved.
